Sosimerasib is an orally active KRAS G12C inhibitor. Sosimerasib can be used in research related to non-small cell lung cancer [1].
In Vitro, Sosimerasib exerts functional inhibitory effects on KRASG12C mutant proteins[1].
References:
[1]. Jia Zhong, et al. Sosimerasib monotherapy in patients with previously treated KRAS G12C–mutated non-small cell lung cancer: Primary results of a phase 2 study. Journal of Clinical Oncology Volume 43, Number 16_suppl June 2025.
In Vitro, Sosimerasib exerts functional inhibitory effects on KRASG12C mutant proteins[1].
References:
[1]. Jia Zhong, et al. Sosimerasib monotherapy in patients with previously treated KRAS G12C–mutated non-small cell lung cancer: Primary results of a phase 2 study. Journal of Clinical Oncology Volume 43, Number 16_suppl June 2025.